Correlation Between Veracyte and Allogene Therapeutics

Can any of the company-specific risk be diversified away by investing in both Veracyte and Allogene Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Allogene Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Allogene Therapeutics, you can compare the effects of market volatilities on Veracyte and Allogene Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Allogene Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Allogene Therapeutics.

Diversification Opportunities for Veracyte and Allogene Therapeutics

-0.61

Correlation Coefficient

Veracyte  Allogene Therapeutics

Excellent diversification

The 3 months correlation between Veracyte and Allogene is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Allogene Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allogene Therapeutics and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Allogene Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allogene Therapeutics has no effect on the direction of Veracyte i.e., Veracyte and Allogene Therapeutics go up and down completely randomly.

Pair Corralation between Veracyte and Allogene Therapeutics

Given the investment horizon of 90 days Veracyte is expected to generate 0.54 times more return on investment than Allogene Therapeutics. However, Veracyte is 1.84 times less risky than Allogene Therapeutics. It trades about 0.11 of its potential returns per unit of risk. Allogene Therapeutics is currently generating about -0.08 per unit of risk. If you would invest  3,426  in Veracyte on September 23, 2024 and sell it today you would earn a total of  663.00  from holding Veracyte or generate 19.35% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Allogene Therapeutics

Veracyte

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Allogene Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Allogene Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Veracyte and Allogene Therapeutics

The main advantage of trading using opposite Veracyte and Allogene Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Allogene Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will offset losses from the drop in Allogene Therapeutics' long position.

The idea behind Veracyte and Allogene Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.